glucoton mr 30 mg comprimate cu eliberare modificată
gm pharmaceuticals ltd. - gliclazidum - comprimate cu eliberare modificată - 30 mg
glyclada 30 mg comprimate cu eliberare prelungită
krka d.d., novo mesto - gliclazidum - comprimate cu eliberare prelungită - 30 mg
gliclazida terapia 60 mg
terapia s.a. - gliclazidum - compr. elib. mod. - 60mg - antidiabetice orale sulfonamide
glyclada 60 mg comprimate cu eliberare prelungită
krka d.d., novo mesto - gliclazidum - comprimate cu eliberare prelungită - 60 mg
glyclada 30 mg comprimate cu eliberare prelungită
krka d.d., novo mesto - gliclazidum - comprimate cu eliberare prelungită - 30 mg
esquel 80 mg
gedeon richter romania s.a. - romania - gliclazidum - compr. - 80mg - antidiabetice orale si parenterale , exclusiv insuline sulfonamide, derivati de uree
diaprel mr comprimate cu eliberare modificata 30 mg
les laboratoires servier - comprimate cu eliberare modificata - 30 mg
glyclada 30 mg
krka, d.d., novo mesto - slovenia - gliclazidum - compr. cu elib. prel. - 30mg - antidiabetice orale si parenterale , exclusiv insuline sulfonamide
galvus
novartis europharm limited - vildagliptin - diabetul zaharat, tip 2 - medicamente utilizate în diabet - vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control.
jalra
novartis europharm limited - vildagliptin - diabetul zaharat, tip 2 - dipeptidyl peptidase 4 (dpp-4) inhibitors, drugs used in diabetes - vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 și 5. 1 pentru datele disponibile pe diferite combinații).